ABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Choledocholithiasis/physiopathology , CA-19-9 Antigen/analysis , Biomarkers, Tumor/analysis , Smoking , Alcohol Drinking , Diagnosis, DifferentialSubject(s)
CA-19-9 Antigen/analysis , Choledocholithiasis/blood , Aged , Biomarkers , Cholecystectomy , Choledocholithiasis/complications , Choledocholithiasis/diagnostic imaging , Choledocholithiasis/surgery , Diagnosis, Differential , Female , Humans , Jaundice, Obstructive/etiology , Neoplasms/diagnosis , Sphincterotomy, Endoscopic , Tomography, X-Ray ComputedABSTRACT
INTRODUCCIÓN: La hemorragia digestiva alta por varices esofagogástricas (HDA por VEG) puede desencadenar una isquemia hepática aguda (IHA). El objetivo de este estudio fue analizar la incidencia de IHA tras una HDA por VEG, los factores de riesgo y su mortalidad. PACIENTES Y MÉTODOS: Estudio retrospectivo sobre pacientes cirróticos con HDA por VEG. Se clasificaron en 2 grupos, determinados por el desarrollo o no de una IHA. Definimos IHA como AST y ALT por encima de 10 veces el valor basal, descartando otras causas de hepatitis aguda. El tratamiento inicial estándar fue soporte hemodinámico, endoscopia urgente con ligadura con bandas y/o escleroterapia, somatostatina y antibióticos. En caso de fracaso de estas medidas, se recurrió a la implantación de una derivación portosistémcica percutánea intrahepática (DPPI). Ambos grupos (IHA y no-IHA) fueron comparados. RESULTADOS: Durante un periodo de 5 años, se recogieron 68 pacientes con HDA por VEG. La incidencia de IHA fue del 16,2%. Tras el análisis univariante, los factores asociados con IHA fueron la diabetes mellitus (OR: 7,5; IC: 1,9-29), shock (OR: 8,5; IC: 2,06-34) y la persistencia de la hemorragia (OR: 9, IC: 1,6-49, p = 0,03). En el análisis multivariante solo mostraron significación estadística la diabetes mellitus (OR: 8,61; IC: 1,4-52,5) y el shock (OR: 7,58; IC: 1,26-45,51). La mortalidad del grupo de IHA fue mayor (45%) que en el grupo no-IHA (10,5%) (p = 0,012). CONCLUSIONES: La IHA tras una hemorragia digestiva por VEG en el paciente cirrótico ocurrió en el 16,2%, asociándose con un peor pronóstico y una mortalidad del 45%. Nuestros resultados sugieren que la diabetes mellitus y el shock hipovolémico son factores de riesgo para el desarrollo de IHA. La detección precoz de estos pacientes en riesgo podría por tanto ayudar a prevenir la IHA
INTRODUCTION: Variceal upper gastrointestinal bleeding (UGIB) can trigger acute hypoxic hepatitis (AHH). The aim of this study was to analyse the incidence, associated risk factors and mortality of AHH after variceal UGIB. PATIENTS AND METHODS: Retrospective study of cirrhotic patients with variceal UGIB, classified into 2 groups according to the development of AHH. AHH was diagnosed when AST and ALT reached levels 10 times above the upper limit of normal, after ruling out other causes of hepatitis. The standard initial treatment consisted of haemodynamic support, emergency endoscopy with rubber band ligation, somatostatin and antibiotics. In the case of failure of primary haemostasis, a transjugular intrahepatic portosystemic shunt (TIPS) was implanted. Both groups (AHH and non-AHH) were compared. RESULTS: Sixty-eight cirrhotic patients with variceal UGIB admitted to the gastroenterology department of Hospital Ramón y Cajal between January 2007 and March 2012 were analysed. Eleven of these patients (16.2%) developed AHH. Univariate analysis showed the following items as risk factors: diabetes (OR: 7.5; CI: 1.9-29), shock (OR: 8.5; CI: 2.06-34) and persistent bleeding (OR: 9.0, CI: 1.6-49, P = .03). However, multivariate analysis confirmed only diabetes (OR: 8.61; CI: 1.4-52.5) and shock (OR: 7.58; CI: 1.26-45.51) as risk factors. Mortality rate in the AHH group was 45%, compared to 10.5% in the non-HAA group (P = .012). CONCLUSIONS: AHH after variceal UGIB occurred in 16.2% of cirrhotic patients and was associated with a poorer prognosis, with a mortality rate of 45%. Our findings suggest that diabetes and shock are risk factors for the development of AHH. Early identification of at-risk patients could therefore help prevent AHH
Subject(s)
Humans , Esophageal and Gastric Varices/complications , Gastrointestinal Hemorrhage/etiology , Ischemia/etiology , Risk Factors , Liver Diseases/etiology , Retrospective Studies , Liver Failure, Acute/etiology , Hypertension, Portal/complicationsABSTRACT
INTRODUCTION: Variceal upper gastrointestinal bleeding (UGIB) can trigger acute hypoxic hepatitis (AHH). The aim of this study was to analyse the incidence, associated risk factors and mortality of AHH after variceal UGIB. PATIENTS AND METHODS: Retrospective study of cirrhotic patients with variceal UGIB, classified into 2 groups according to the development of AHH. AHH was diagnosed when AST and ALT reached levels 10 times above the upper limit of normal, after ruling out other causes of hepatitis. The standard initial treatment consisted of haemodynamic support, emergency endoscopy with rubber band ligation, somatostatin and antibiotics. In the case of failure of primary haemostasis, a transjugular intrahepatic portosystemic shunt (TIPS) was implanted. Both groups (AHH and non-AHH) were compared. RESULTS: Sixty-eight cirrhotic patients with variceal UGIB admitted to the gastroenterology department of Hospital Ramón y Cajal between January 2007 and March 2012 were analysed. Eleven of these patients (16.2%) developed AHH. Univariate analysis showed the following items as risk factors: diabetes (OR: 7.5; CI: 1.9-29), shock (OR: 8.5; CI: 2.06-34) and persistent bleeding (OR: 9.0, CI: 1.6-49, P=.03). However, multivariate analysis confirmed only diabetes (OR: 8.61; CI: 1.4-52.5) and shock (OR: 7.58; CI: 1.26-45.51) as risk factors. Mortality rate in the AHH group was 45%, compared to 10.5% in the non-HAA group (P=.012). CONCLUSIONS: AHH after variceal UGIB occurred in 16.2% of cirrhotic patients and was associated with a poorer prognosis, with a mortality rate of 45%. Our findings suggest that diabetes and shock are risk factors for the development of AHH. Early identification of at-risk patients could therefore help prevent AHH.
Subject(s)
Esophageal and Gastric Varices/complications , Gastrointestinal Hemorrhage/complications , Ischemia/etiology , Liver/blood supply , Adult , Aged , Carcinoma, Hepatocellular/epidemiology , Comorbidity , Diabetes Complications/epidemiology , Female , Humans , Ischemia/mortality , Liver Diseases, Alcoholic/epidemiology , Liver Neoplasms/epidemiology , Male , Middle Aged , Portal Vein , Recurrence , Retrospective Studies , Risk Factors , Thrombosis/epidemiologyABSTRACT
INTRODUCCIÓN: El tratamiento de la hepatitis crónica B antígeno e negativa (HCB HBeAg negativa) con antivíricos orales (AO) suele prolongarse de forma indefinida debido a que la pérdida del antígeno de superficie como objetivo para su suspensión es un hecho infrecuente. Recientemente han aparecido las primeras evidencias que sugieren finalizar la terapia con AO en casos seleccionados. OBJETIVOS: Analizar la tasa de rebote virológico en pacientes con HCB Age negativa que suspendieron el tratamiento con AO. MATERIAL Y MÉTODOS: Estudio retrospectivo observacional que incluyó 140 casos de HCB HBeAg negativa. Veintidós pacientes, que recibieron exclusivamente AO, los suspendieron por diversos motivos realizándose un seguimiento posterior. Todos presentaban transaminasas normales, ADN indetectable y ausencia de cirrosis o comorbilidades importantes al finalizar el tratamiento. RESULTADOS: Doce pacientes presentaron rebote virológico (54,54%), transcurriendo una media de 6,38 meses (± 1,9) desde la suspensión hasta el rebote (el 75% dentro de los 12 primeros meses tras la suspensión). Cinco recibieron adefovir, uno lamivudina más adefovir, uno tenofovir y 5 lamivudina. La duración media del tratamiento, desde el inicio hasta la suspensión, fue de 38,5 meses (± 4,5). El grupo con respuesta sostenida presentaba una edad media y duración del tratamiento superior a los sujetos con rebote, si bien estas diferencias no resultaron estadísticamente significativas. CONCLUSIONES: Los resultados sugieren que es posible suspender la terapia con AO en casos seleccionados de HCB Age negativa, siempre que no exista cirrosis, se cumpla un tiempo mínimo de tratamiento, las transaminasas sean normales y el ADN indetectable de forma mantenida. En estos casos, se debe realizar un seguimiento estrecho durante el primer año y posteriormente de forma indefinida
BACKGROUND: Treatment of HBeAg-negative chronic hepatitis B (CHB) with nucleos(t)ide analogues (NA) is usually indefinite, since the loss of HBsAg, as a criterion for its discontinuation, is a rare event. Recent evidence suggests that discontinuing NA therapy may be feasible in selected patients. OBJECTIVES: To analyze the rate of virological relapse in patients with HBeAg-negative CHB who discontinued treatment with NAs. METHODS: We performed a single-center observational study that included 140 patients with HBsAg-negative CHB. Twenty-two patients, who received only NAs, discontinued treatment for different reasons and were subsequently monitored. All had normal ALT and AST, undetectable DNA and absence of cirrhosis or significant comorbidities before stopping treatment. RESULTS: Twelve patients showed virologic relapse (54.54%). The mean interval between discontinuation and relapse was 6.38 months (± 1.9) (75% relapsed during the first 12 months after discontinuation). Five received adefovir, 1 lamivudine and adefovir, 1 tenofovir and 5 lamivudine alone. The mean treatment duration in this group was 38.5 months (± 4.5). The sustained response group had a higher mean age and longer treatment duration than patients with virologic relapse but these differences were not statistically significant. CONCLUSIONS: The results suggest that NA treatment can be stopped in selected patients with CHB as long as they are not cirrhotic, have completed a minimum period of treatment, have normal ALT and sustained undetectable DNA. These patients should be closely monitored during the first year and then indefinitely
Subject(s)
Humans , Antiviral Agents/therapeutic use , Hepatitis B, Chronic/drug therapy , Withholding Treatment , Hepatitis B virus/pathogenicity , Rebound Effect , Hepatitis B Antigens , Viral Load , Retrospective StudiesABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Carcinoma, Hepatocellular/pathology , Hepatitis C, Chronic/complications , Liver Neoplasms/pathology , Neoplasm Metastasis , Orbital Neoplasms/secondaryABSTRACT
BACKGROUND: Treatment of HBeAg-negative chronic hepatitis B (CHB) with nucleos(t)ide analogues (NA) is usually indefinite, since the loss of HBsAg, as a criterion for its discontinuation, is a rare event. Recent evidence suggests that discontinuing NA therapy may be feasible in selected patients. OBJECTIVES: To analyze the rate of virological relapse in patients with HBeAg-negative CHB who discontinued treatment with NAs. METHODS: We performed a single-center observational study that included 140 patients with HBsAg-negative CHB. Twenty-two patients, who received only NAs, discontinued treatment for different reasons and were subsequently monitored. All had normal ALT and AST, undetectable DNA and absence of cirrhosis or significant comorbidities before stopping treatment. RESULTS: Twelve patients showed virologic relapse (54.54%). The mean interval between discontinuation and relapse was 6.38 months (± 1.9) (75% relapsed during the first 12 months after discontinuation). Five received adefovir, 1 lamivudine and adefovir, 1 tenofovir and 5 lamivudine alone. The mean treatment duration in this group was 38.5 months (± 4.5). The sustained response group had a higher mean age and longer treatment duration than patients with virologic relapse but these differences were not statistically significant. CONCLUSIONS: The results suggest that NA treatment can be stopped in selected patients with CHB as long as they are not cirrhotic, have completed a minimum period of treatment, have normal ALT and sustained undetectable DNA. These patients should be closely monitored during the first year and then indefinitely.
Subject(s)
Alanine Transaminase/blood , Antiviral Agents/therapeutic use , Hepatitis B e Antigens/immunology , Hepatitis B, Chronic/drug therapy , Nucleotides/therapeutic use , Adult , Aged , Aspartate Aminotransferases/blood , DNA, Viral/isolation & purification , Drug Therapy, Combination , Female , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Hepatitis B virus/isolation & purification , Hepatitis B, Chronic/immunology , Humans , Liver Cirrhosis/drug therapy , Male , Middle Aged , Recurrence , Treatment OutcomeABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Celiac Disease/chemically induced , Celiac Disease/complications , Celiac Disease/diagnosis , Angiotensin I/adverse effects , Angiotensin I/therapeutic use , Angiotensin II/adverse effects , Angiotensin II/therapeutic use , Diarrhea/complications , Diarrhea/diagnosis , Diarrhea/drug therapy , Hypertension/complications , Hypertension/diagnosis , Clostridioides difficile/isolation & purification , Microscopy, Fluorescence/methods , Fluorescent Antibody Technique, Direct , Diagnosis, DifferentialABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Pulsed Radiofrequency Treatment/methods , Nerve Compression Syndromes/therapy , Amitriptyline/therapeutic use , GABA Agents/therapeutic use , Overweight/complicationsABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Pancreatic Diseases/enzymology , Drug Hypersensitivity/diagnosis , Eosinophilia/etiology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Pancreatic Function Tests , Edema/etiologyABSTRACT
Syphilis is a chronic systemic infection mainly transmitted through sexual contact that shows a great variety of clinical manifestations. Liver involvement is an unusual complication mainly reported in HIV patients. In this case report we present a case of a 42-year-old immunocompent man with acute cholestatic hepatitis who was finally diagnosed of luetic hepatitis. Liver disease was the only manifestation of syphilis infection difficulty it's diagnostic. We emphasize the importance of including syphilis in the differential diagnosis of abnormal liver function tests in patients at risk of sexually transmitted diseases due to its resolution with appropriate antibiotic treatment.
Subject(s)
Hepatitis/microbiology , Syphilis/complications , Acute Disease , Adult , Hepatitis/diagnosis , Humans , Immunocompetence , Male , Syphilis/diagnosisSubject(s)
Nerve Compression Syndromes/therapy , Pain Management/methods , Pulsed Radiofrequency Treatment , Abdomen/innervation , Adult , Amines/therapeutic use , Amitriptyline/therapeutic use , Anesthetics, Local/therapeutic use , Combined Modality Therapy , Cyclohexanecarboxylic Acids/therapeutic use , Emergencies , Female , Gabapentin , Humans , Nerve Block , Nerve Compression Syndromes/drug therapy , Skin/innervation , Triamcinolone Acetonide/therapeutic use , gamma-Aminobutyric Acid/therapeutic useSubject(s)
Amylases/blood , Atorvastatin/adverse effects , Drug Hypersensitivity Syndrome/diagnosis , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Lipase/blood , Adrenal Cortex Hormones/therapeutic use , Atorvastatin/therapeutic use , Drug Eruptions/blood , Drug Eruptions/diagnosis , Drug Eruptions/drug therapy , Drug Eruptions/etiology , Drug Hypersensitivity Syndrome/blood , Drug Hypersensitivity Syndrome/drug therapy , Drug Hypersensitivity Syndrome/etiology , Edema/chemically induced , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Middle AgedSubject(s)
Antihypertensive Agents/adverse effects , Imidazoles/adverse effects , Malabsorption Syndromes/chemically induced , Tetrazoles/adverse effects , Aged , Antihypertensive Agents/therapeutic use , Atrophy , Celiac Disease/diagnosis , Chronic Disease , Diagnosis, Differential , Diarrhea/chemically induced , Diarrhea/pathology , Duodenum/immunology , Duodenum/pathology , Humans , Hypertension/complications , Hypertension/drug therapy , Imidazoles/therapeutic use , Immunophenotyping , Intestinal Mucosa/ultrastructure , Lymphocyte Subsets/immunology , Malabsorption Syndromes/diagnosis , Malabsorption Syndromes/pathology , Male , Microvilli/pathology , Tetrazoles/therapeutic useABSTRACT
INTRODUCCIÓN: La globalización y los movimientos migratorios hacen que la hepatitis crónica B Age+ (HCBe+) cobre cada día mayor relevancia en nuestro entorno. Objetivo Analizar las características epidemiológicas, evolución y respuesta al tratamiento con antivirales orales (AO) de los pacientes con HCBe+.Material y métodosSe analizaron 436 casos de infección crónica por el virus de la hepatitis B atendidos en el Hospital Universitario Ramón y Cajal desde 1990 hasta junio del 2012.ResultadosSesenta y cinco (14,9%) presentaban HCBe+. Siete pacientes en fase de tolerancia inmune no fueron tratados; los 58 restantes, sí. Fueron excluidos 4: 2 hepatitis agudas graves, una coinfección por VHC y otro por virus Delta. De los 54 restantes, 19 recibieron interferón con o sin AO y 35 solo Dos tratados durante menos de un mes no fueron incluidos en el análisis. Este se realizó finalmente en 33 pacientes. Duración media del tratamiento: 46,81 meses (6-138). Lamivudina fue el fármaco más prescrito (39,39%), seguida de tenofovir (24,24%) y entecavir (21,21%). Edad media: 42,08 ± 14 años; varones 75,75% (25/33). El 57,57% (19/33) seroconvirtió el antígeno e y el 27,27% (9/33) eliminó el antígeno de superficie. No se objetivó la reaparición de este último tras un seguimiento medio de 35,6 meses. Resistencias: 8 casos en 7 pacientes, 7 a lamivudina y uno a adefovir. CONCLUSIONES: El 15% de las HCB en nuestro medio son e+. El tratamiento con AO logra una elevada tasa de seroconversión (57,57%) y un considerable porcentaje de pérdida del antígeno de superficie (27,27%)
INTRODUCTION: Due to globalization and migratory movements, HBeAg+ chronic hepatitis B isbecoming increasingly important in Spain. OBJECTIVE: To analyze the epidemiological features, progression, and treatment response to oral antiviral agents (OA) in HBeAg+ chronic hepatitis B patients in our area. MATERIAL AND METHODS: We analyzed 436 patients with chronic hepatitis B infection followed up at the Ramón y Cajal Hospital from 1990 to June 2012. RESULTS: Sixty-five patients (14.9%) had HBeAg+ chronic hepatitis B. Seven patients in the immunotolerant phase were not treated, while the remaining 58 received treatment. Four patients were excluded: two due to severe acute hepatitis, one due to hepatitis C virus coinfection and another because of a Delta virus coinfection. Of the remaining 54 patients, 19 received interferon with or without OA, and 35 received only OA. Two patients treated for less than 1 month were not included in the analysis. The analysis was finally performed in 33 patients. The mean duration of treatment was 46.81 months (6-138). Lamivudine was the most frequently prescribed drug (39.39%) followed by tenofovir (24.24%) and entecavir (21.21%). The mean age was 42.08 ± 14 years and 75.75% (25/33) of the patients were male. Nineteen of 33 patients (57.57%) achieved seroconversion to anti-HBe, and 27.27% (9/33) showed clearance of HBsAg. There was no evidence of HBsAg reversion after a mean follow-up of 35.6 months. There were 8 cases of resistance in 7 patients: 7 to lamivudine and 1 to adefovir. CONCLUSIONS: Approximately 15% of chronic hepatitis B patients in our area are HBeAg+. Treatment with OA achieves a high seroconversion rate (57.57%) and a considerable percentage of HBsAg clearance (27.27%)
Subject(s)
Humans , Hepatitis B, Chronic/drug therapy , Antiviral Agents/therapeutic use , Hepatitis Antigens/isolation & purification , Emigration and Immigration/statistics & numerical data , /epidemiology , Epidemiology, DescriptiveABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Panniculitis, Peritoneal/diagnosis , Tomography, X-Ray Computed/methods , Abdominal Pain/etiology , Chronic Disease , Tamoxifen/therapeutic useABSTRACT
INTRODUCTION: Due to globalization and migratory movements, HBeAg+ chronic hepatitis B is becoming increasingly important in Spain. OBJECTIVE: To analyze the epidemiological features, progression, and treatment response to oral antiviral agents (OA) in HBeAg+ chronic hepatitis B patients in our area. MATERIAL AND METHODS: We analyzed 436 patients with chronic hepatitis B infection followed up at the Ramón y Cajal Hospital from 1990 to June 2012. RESULTS: Sixty-five patients (14.9%) had HBeAg+ chronic hepatitis B. Seven patients in the immunotolerant phase were not treated, while the remaining 58 received treatment. Four patients were excluded: two due to severe acute hepatitis, one due to hepatitis C virus coinfection and another because of a Delta virus coinfection. Of the remaining 54 patients, 19 received interferon with or without OA, and 35 received only OA. Two patients treated for less than 1 month were not included in the analysis. The analysis was finally performed in 33 patients. The mean duration of treatment was 46.81 months (6-138). Lamivudine was the most frequently prescribed drug (39.39%) followed by tenofovir (24.24%) and entecavir (21.21%). The mean age was 42.08±14 years and 75.75% (25/33) of the patients were male. Nineteen of 33 patients (57.57%) achieved seroconversion to anti-HBe, and 27.27% (9/33) showed clearance of HBsAg. There was no evidence of HBsAg reversion after a mean follow-up of 35.6 months. There were 8 cases of resistance in 7 patients: 7 to lamivudine and 1 to adefovir. CONCLUSIONS: Approximately 15% of chronic hepatitis B patients in our area are HBeAg+. Treatment with OA achieves a high seroconversion rate (57.57%) and a considerable percentage of HBsAg clearance (27.27%).
Subject(s)
Antiviral Agents/administration & dosage , Hepatitis B, Chronic/drug therapy , Administration, Oral , Adult , Aged , Female , Hepatitis B e Antigens/blood , Hepatitis B, Chronic/blood , Humans , Male , Middle Aged , Treatment OutcomeABSTRACT
No disponible